Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Hold rating on Zogenix (NASDAQ:ZGNX) on Friday, setting a price target of $25, which is approximately 0.89% above the present share price of $24.78.
Higgins expects Zogenix to post earnings per share (EPS) of -$0.54 for the third quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Zogenix, with an average price target of $46.29.
The analysts price targets range from a high of $68 to a low of $25.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $1.25 million and a net profit of -$54.81 million. The company’s market cap is $1.37 billion.
According to TipRanks.com, Ladenburg Thalmann & Co. analyst Michael Higgins is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.3% and a 30.95% success rate.
Zogenix, Inc. is a pharmaceutical company. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.